Brad Wouters, Executive Vice-President of Science and Research at University Health Network, shared on LinkedIn:
“After curative cancer treatment, one question lingers for patients: is the cancer truly gone?
That’s what SHERLOCK is built to answer. The Princess Margaret study follows 7,000 patients after treatment, using blood tests to detect molecular residual disease – traces of cancer too small for CT, MRI or tissue biopsy to catch.
Finding those signals earlier could let clinicians monitor patients more closely, intensify treatment when relapse is likely, or scale back when it isn’t – and, in time, intercept recurrence rather than wait for it.
Led by Dr. Lillian Siu, scientific lead at the Peter Gilgan Centre for Early Cancer Detection Research, SHERLOCK is also building what is expected to become the world’s largest dataset of its kind – an engine for the next generation of early-detection trials.
This is early detection as prevention, not just diagnosis.”
You can also read: Why Cancer Comes Back: The Biology of Cancer Recurrence and Relapse
